Superfractionation radiation therapy in the treatment of malignant astrocytoma.
Superfractionation (SF) radiation therapy is the administration of three fractions per day. We have assessed the effect of SF in a prospective randomized clinical study of malignant astrocytomas from July 1978 to December 1980. Thirty-five patients were randomized to SF (4000 rad in 45 fractions in 3 weeks whole brain and 1000 rad in five fractions in one week local boost). Thirty-four patients were randomized to conventional fractions (3400 rad in 17 fractions whole brain in 3.5 weeks and 1600 rad in eight fractions in 1.5 weeks local boost). Both treatment arms received chemotherapy with CCNU. The 1- and 2-year actuarial survival rate is 54% and 21% for SF group and 32% and 10% for CF group. The other advantages of SF include shorter mean duration of steroid administration and improved performance status following radiation therapy.
D000367:Age Factors; D001254:Astrocytoma / Q000532:radiotherapy* / Q000601:surgery; D001932:Brain Neoplasms / Q000532:radiotherapy* / Q000601:surgery; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011878:Radiotherapy / Q000379:methods*; D011879:Radiotherapy Dosage; D011897:Random Allocation